

Visioneering Technologies, Inc.

December 2017



Disclaimer

The material contained in this document is a presentation of general information about the activities of Visioneering Technologies, Inc. (“VTI”, or “Visioneering”) current as at the date of this presentation. The information is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision. VTI is not licensed to provide financial product advice in respect of its securities or any other financial products.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs, including but not limited to, statements related to VTI’s financial performance, business strategy and goals, plans and prospects, potential benefits of its products and technology, product development, timing of international regulatory approvals, market size, commercial success, and future financial performance. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results may differ materially from what is expressed in this presentation.


The information in this presentation is subject to change and unless required by law, VTI assumes no obligation to update this presentation or its contents for any matter arising or coming to VTI’s notice after the date of this presentation.

To the extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by VTI or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction

Company Overview

- Founded in 2008 with the aim of commercialising its Neurofocus Optics technology
- Developed a proprietary daily-disposable contact lens called NaturalVue® Multi-Focal (NaturalVue MF) which has unique properties to address two major eye care applications:
 - Presbyopia – progressive loss of ability to see near objects, in people over 40
 - Paediatric Myopia – inability to see far objects, starting in childhood and worsening until early adulthood
- Successful ASX IPO in March 2017 raised A\$33.3m
- Successfully initiated and now expanding commercial launch of NaturalVue MF in US
- Headquartered in Atlanta, Georgia, with ~45 FTEs




Investment Highlights

- Large addressable markets (estimated >US\$5.4bn in the US alone) and favourable competitive landscape
- All current & planned products FDA cleared, key international clearances in progress
- Patents issued and pending around the world covering design and uses of NVMF
- Value proposition – provides superior near, intermediate and distant vision in presbyopes and addresses optical risk factors for progression of near-sightedness in children
- Expanding sales infrastructure and product sales:
 - Experiencing strong growth and excellent early momentum in US sales
 - Additional product launches planned for 2018
 - Opportunities for international expansion in 2018

Strong US Sales Momentum

3Q17 Revenue up 90% QoQ, Active Accounts up 79%


- 20 experienced reps (many joined from competing contact lens companies) added in 2017, 25 reps in total
 - 43 of 50 states now covered in US
 - Targeting up to 45 total reps in 2018
- Focused on building base of users (expansion of active accounts)
- Peer-to-peer networking and data publications resulting in rapid increase in in-bound inquiry
- Each sales rep targeted to service between 100-200 accounts (depending upon geography) within 12 months of completing training
- At maturity, an account targeted to deliver US\$5,000-\$12,000 per year



How the Optics in the Normal Eye Bend Light

Normal Vision


1. Light reflects from an object into the eye
2. Light rays are first bent inward by the cornea, and then again by crystalline lens
3. Light rays converge onto the retina, producing a clear image



What Could Go Wrong?


Presbyopia

- Age-related weakening of crystalline lens
- Light from near objects not bent sufficiently, resulting in image forming behind the retina (blur)
- 'Relative plus lens' is needed to increase light bend, converging light onto the retina



Myopia

- Light bent too much relative to the length of the eye
- Results in image forming in front of the retina (blur)
- 'Minus lens' is needed to unbend the light so it converges on the retina



Presbyopia

- Presbyopia is the age-related loss of near vision
- Affects most people over the age of 40
- The need is for simultaneous clear near and distance vision as one ages

After 40, near vision progressively deteriorates →

Age 30



Age 40



Age 45



Presbyopia Challenges Existing Contact Lenses

Currently marketed MF contact lenses have two major shortcomings:

Poor Clinical Performance


- Current MF contact lenses make most patients compromise either their near or distance vision
- Poor performance in near vision is the leading reason why MF contact lenses fail for patients today
- Often, patients need to supplement their MF contact lenses with reading eyeglasses in order to perform near vision tasks

Difficult and Time Consuming for Eye Care Professionals to Fit

- A high number of possible lens permutations make fitting MF contact lenses a frustrating and time-consuming endeavour for both patient and eye care professional
- Two or more sessions with an eye care professional are required in the majority of cases to find (fit) the correct lens for the patient
- Typically the patient only pays a flat fitting fee regardless of the number of fitting visits, so the fewer fitting visit required, the better the eye care professional's economics

How Visioneering's NaturalVue Lens Works in Presbyopia

Visioneering's Neurofocus Optics work similarly to a pinhole aperture: Unfocused light rays are blocked, while focused light rays pass through the aperture and result in clear focus of near objects




The Revolutionary NaturalVue MF Contact Lens

NaturalVue MF Contact Lens



Visual Correction



Visual Information

Rapid increase in optical power towards the outside of the lens results in “peripheral blur” which is blocked out by the patient’s brain

Centre of the lens provides the correction for distance vision

Rapid increase in optical power towards the outside of the lens results in “peripheral blur” which is blocked out by the patient’s brain

This revolutionary optical design simultaneously provides:


- Clear near, intermediate, and distance vision;
- Excellent depth perception without effecting peripheral vision; and
- A much easier and quicker fitting process

Performance Benefits of NaturalVue Contact Lenses

Superior clinical performance...

- The NaturalVue MF contact lens solves the near vision problem, simultaneously providing superior near, intermediate, and distance vision


PMET Trial – Near, Intermediate, and Distance Vision (n=59)



...And much easier to fit

- Currently marketed MF contact lenses require multiple visits (up to 6) to achieve a successful fit a majority of the time¹
- In Visioneering's clinical trial, NaturalVue was successfully fit in an average of 1.1 visits, versus 2.4 for a leading MF competitor²


Average fitting visits – NaturalVue MF vs Competitor MF



- As reported by eye care professionals when fitting presbyopic patients
- As reported by the manufacturer of the contact lens

Large Presbyopia Addressable Market Globally

- Most people become Presbyopic around the age of 40, and the condition worsens with age
- In the US alone, the addressable market is estimated at US\$3.4 billion per annum:




- Upside to the addressable market - large population of additional patients who currently give up contact lenses for eyeglasses when they become Presbyopic due to shortcomings of currently marketed MF contact lenses
- Significant additional addressable markets – Asia, Europe, Australia, Canada, Americas

Paediatric Myopia and Myopia Progression in Children

- Paediatric Myopia is nearsightedness that develops in early childhood, causing blurred distance vision
- A child's Myopia will continue to worsen until early adulthood (age 18-25); this is termed Myopia Progression
- The WHO cited under-corrected Myopia as the most common cause of visual impairment globally
- Myopia rates have undergone explosive growth on a global scale over the past four decades



Estimated prevalence of Myopia in young adults¹



Myopia Progression is a serious medical problem, correlating to significantly higher risk of developing serious eye problems

4-16x increase of
Retinal Detachment

2-5x increase of
Cataracts

4x increase of
Glaucoma

Options Available to Slow Myopia Progression are Limited

- Glasses or most contacts only correct Myopia, but have little to no impact on slowing the progression of Myopia
- Myopia Progression is caused by the continued lengthening of the eye, and generally remains untreated owing to the poor treatment options available:

Atropine

Overview

Drug formulated as eye drops or ointment for the eye

Drawbacks

- Uncertain efficacy
- Significant side effects
- Rebound effect
- Temporary use only
- Difficult to obtain




Ortho-K

Overview

Specially designed hard contact lenses worn at night to reshape the front surface of the eye

Drawbacks

- Undesirable complications
 - Infection, inflammation & discomfort
- Requires daily lens care
- Daily revision to prior shape
- Expensive




Soft Contact Lenses

Overview

High interest in soft contact lenses for Myopia Progression control

Drawbacks


- Several past and present attempts
- None have achieved widespread adoption
- Highly variable published data
- Lack sufficient peripheral 'plus' power to maximise the slowing of Myopia



Simple Myopia Sight Correction Exacerbates Myopia Progression

- Glasses or contact lenses correct a patient's Myopic vision at the centre of the retina to provide clear distance vision
- A by-product of this central correction is that peripheral light rays are moved behind the retina, which creates a growth signal for the lengthening of the eyeball
- This cycle of central correction leading to eye growth repeats itself over and over, resulting in higher and higher amounts of Myopia (a.k.a. Myopia Progression) throughout adolescence

Traditional contact lenses or glasses correct vision for Myopia but do not address Myopia Progression




The NaturalVue MF lens simultaneously corrects Myopia and moves the light at the periphery of the Retina forward, thus removing or reducing the growth signals that lengthen the eye

Outstanding New Published Data for NaturalVue MF in Myopia Progression

- New peer-reviewed study (October 2017) published by some of the leading experts in treating paediatric myopia showed in 32 children:
 - ~96% average decrease in rate of myopia progression
 - ~98% of children showed a decrease in myopia progression
 - ~81% of children showed a complete halt of progression, including some showed some reversal
- Compelling strength of data is driving added awareness and strong inbound enquiries from eye-care professionals

Annualised Myopia Progression in children wearing NaturalVue MF¹



1. Eye and Contact Lens, Epub 2017

Large Paediatric Myopia Progression Addressable Market

- In the US alone, the addressable market is estimated at US\$2.0 billion per annum

US Paediatric Myopia Progression Addressable Market



42 million

US population
8 - 17 years of age



13 million

32% are Myopic



5 million

35% use contact
lenses



85.5%

replacement compliance
rate

US addressable market = 5m patients x 85.5% compliance rate x \$500 p.a. = US\$2.0 billion p.a.

- Potential upside to the addressable market is available by targeting the large population of additional patients that might be converted from eyeglasses to contact lenses
- Still larger addressable markets in Asia where rates of myopia in children are as high as 90%+

Strong Support from Optometrists

"I recently had a 9-year old highly myopic child who was worsening by more than a diopter per year for several years in a row. Orthokeratology had failed to help her. I fit her with NVMF, which both corrected her vision, and slowed her progression in one eye by 75% and completely stopped the progression in the other eye."

Justin Kwan, OD, FAAO, Associate Professor SCCO

"I started using NVMF for myopic children, and have seen a profound reduction of myopia progression in the children I put in this lens. More recently, I have started using NVMF in presbyopic adults, and have been able to provide excellent distance and near vision even in patients who have failed other solutions. I even successfully fit my wife, who had failed in and rejected the other multi-focal lenses."

Tom Aller, OD, FAAO, Lecturer, Adjunct Professor

"Due to its ease-of-fitting and daily disposable modality, the NaturalVue Multifocal has rapidly become the most valuable tool in my practice's expanding myopia management clinic. Over the 18 months I have been fitting the lens, my patients' quality of vision and the efficacy of myopia control with NaturalVue Multifocal have far exceeded my expectations and appeals to a much wider audience than other solutions. This lens really is the future of myopia treatment."

Dr. Brett O'Connor, OD


International Commercialisation Planned to Commence in 2018

- Plan is to partner with leading vision care product distributors in each region:
 - Quicker access to large international markets
 - Leverage an existing distributor's in-country expertise and customer base
 - Cost-effective expansion

Priority Regions

- Asia planned as a region of important focus and growth:
 - Very high prevalence of paediatric Myopia
 - Underpenetrated in terms of contact lens usage relative to US or Europe
 - Numerous approaches by potential distributors – currently in discussions
- CE Marking and TGA approval underway – targeting approval late 2017 - early 2018

Contact Lenses Penetration of Vision Correction Market by Country¹



1. 2015 estimate, Global Industry Analysts, Inc., Contact Lenses and Solutions – A Global Strategic Report (May 2016).

Product Line Extensions for 2018

- VTI launched its Sphere contact lens in 2016, expanded the launch in 2017, and plans to further broaden its product offering with Toric and MF Toric contact lenses
- Promotes brand recognition and increases coverage across the eye care professional's practice
- No additional FDA clearances required – existing FDA clearance for NaturalVue MF contact lens provides coverage for all current and planned NaturalVue contact lenses

NaturalVue Spheres



Visual
Correction

Near / farsightedness

Launched 2016, Expanding 2017

NaturalVue Torics



Visual
Correction

Near / farsightedness
+
Astigmatism

Targeted Launch – Mid 2018

NaturalVue MF Torics



Visual
Correction

Near / farsightedness
+
Astigmatism
+
Presbyopia

Targeted Launch – End 2018

Management Team Experienced in Contact Lens Market



Dr Stephen Snowdy
CEO

- Initially joined VTI as Chairman in May 2009 and has been Chief Executive Officer since June 2013
- 15 years of experience in life science venture investing and executive management
- Doctorate (major in Neurobiology) and Master of Business Administration from the University of North Carolina, and a Bachelor of Science (Major in Chemistry) from the University of Florida



Mr Tony Sommer, Jr.
Senior VP Sales and Marketing

- 20 years' experience in sales and marketing management
- Previously Head of Sales for Bausch & Lomb's US Vision Care division
- Bachelor of Science from the United States Air Force Academy and Master of Business Administration from Oklahoma City University



Dr Sally Dillehay
Chief Medical Officer,
VP, Clinical and
Regulatory Affairs,
Corporate Secretary

- 35 years' experience in research, statistics and clinical trials in optometry
- Previously over 15 years at CIBA Vision, serving in various senior roles, including as Director of Medical Marketing and Clinical Claims Research
- Doctorate of Optometry and Master of Science from The Ohio State University and Doctorate of Education from Nova Southeastern University



Mr Mark Rapoport
CFO

- Over 30 years of experience in Financial Management, HR, Supply Chain Management
- Has served in executive roles in both public and private companies, including CFO at Capsule Technologies SAS (acquired by Qualcomm Life, Inc.), COO/CFO at Landacorp (Nasdaq: LCOR), and Controller at iXL (Nasdaq: IIXL)
- Master of Business Administration-Finance & Accounting from Emory University



Ms Rosa Lee
Executive Director of
Manufacturing and
Engineering

- 14 years' experience in product development in the eyecare industry, including almost 12 years' experience in ophthalmic product development
- Previously at Bausch & Lomb and SynergEyes, Inc
- Master of Science in Biomedical Engineering from the University of Rochester

Backed by a Proven Board



Mr Fred Shwarzer
*Chairman of the Board
and Non-executive
Director*

- Currently serves on the board of Amaranth Medical, Great Lakes Pharmaceuticals, Health Fidelity, IGM Bioscience, Kereos and Mirabilis Medical
- Presently Managing Partner at Charter Life Sciences
- Has led investments in a number of life science companies, including Inviragen (acquired by Takeda Pharmaceuticals)



Ms Christi Van Heek
Non-executive Director

- 25 years of experience in the life sciences industry
- Previously served as Vice President of Global Marketing for Genzyme, amongst other roles (acquired by Sanofi S.A. for >US\$20bn)
- Currently serves on the board of Concert Pharmaceuticals, a NASDAQ listed biotechnology and previously served on the board of Affymax (previously listed on the NASDAQ)



Dr Stephen Snowdy
*CEO and Executive
Director*

- See Management slide



Ms Zita Peach
Non-executive Director

- Over 30 years of experience in the pharmaceutical, biotechnology, medical device & healthcare sectors
- Currently serves on the board of ASX-listed Starpharma Holdings, Monash IVF Group and AirXpanders, in addition to board positions with Bionic Vision Technologies Pty Ltd, Vision Eye Institute Ltd.
- Previously held executive roles at ASX-listed CSL Limited and Fresenius Kabi



Mr Tom Dooley
Non-executive Director

- 30 years of experience in pharma and medical devices, including contact lenses and eye care
- Most recently served as President of Alcon Japan, where he oversaw 1,300 employees, and \$1B in revenue from contact lens products, medical devices, and pharma
- Served as Alcon's country manager in Australia and New Zealand

News Flow 4Q17-2018

Continued expansion of sales activities in the US

Additional peer-reviewed data on use of NaturalVue MF in children

International regulatory approvals:

- CE Mark
 - TGA Approval
-

Commencement of international sales

Further product launches (NaturalVue Toric & NaturalVue MF Toric)
